Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal pigment epithelium (RPE) cellular replacement is a therapeutic approach aimed at restoring or replacing the RPE layer in the retina, primarily to treat degenerative retinal diseases such as age-related macular degeneration (AMD) and Stargardt disease. The goal is to provide a functional RPE monolayer capable of supporting native photoreceptors, revitalizing Bruch’s membrane for proper nutrient/metabolite exchange, and ultimately preserving or restoring vision. Challenges include achieving correct polarization and integration into host tissue, preventing immune rejection, and ensuring long-term functionality of the transplanted cells.
Replacement of dysfunctional or lost RPE cells with functional RPE cells derived from stem cells (hESCs/iPSCs) to restore retinal homeostasis and support photoreceptor function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal Pigment Epithelium Cellular Replacement.